LBRX

The stock is in a strong multi-month uptrend, coiling in an ascending-triangle consolidation at its 52-week high. Price is supported by all rising EMAs and the 200-day SMA, while momentum indicators (RSI and Options Score) suggest further upside is likely. Medium-term bias remains bullish, and short-term conditions are favorable for immediate participation either on minor pullbacks into the 20-day EMA or a breakout above the $49.50 resistance on rising volume.

• ↑LB-102 showed statistically significant Phase 2 NOVA-1 trial efficacy for acute schizophrenia.
• ↑H.C. Wainwright raised its price target to $60, implying ~43% upside.
• ↓Earnings yield at –1.49 and profitability score –0.67 expose weak fundamentals.